[go: up one dir, main page]

AR037459A1 - Antagonistas vi del receptor ccr-3 - Google Patents

Antagonistas vi del receptor ccr-3

Info

Publication number
AR037459A1
AR037459A1 ARP020104582A ARP020104582A AR037459A1 AR 037459 A1 AR037459 A1 AR 037459A1 AR P020104582 A ARP020104582 A AR P020104582A AR P020104582 A ARP020104582 A AR P020104582A AR 037459 A1 AR037459 A1 AR 037459A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylamino
cycloalkyl
hydrogen
halo
Prior art date
Application number
ARP020104582A
Other languages
English (en)
Inventor
Bois Daisy Joe Du
Denis John Kertesz
Eric Brian Sjogren
David Bernard Smith
Qi Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR037459A1 publication Critical patent/AR037459A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)

Abstract

Derivados de piperazina de fórmula (1); los compuestos son útiles como antagonistas de los receptores CCR-3 y por lo tanto pueden ser usados para el tratamiento de las enfermedades mediadas por CCR-3. También son objeto de la presente: método para preparar los compuestos de fórmula (1), una composición y el uso de los compuestos para preparar un medicamento. Reivindicación 1: Un compuesto de fórmula (1) caracterizado porque: R1 es alquileno C1-2; R2 es fenilo opcionalmente sustituido; R3 es hidrógeno, alquilo C1-6, acilo, arilo o arilo-alquilo C1-6; el anillo A es un cicloalquilo C3-7, heterociclilo, o fenilo opcionalmente sustituido; L es -C(=O)-, -C(=S), -SO2-, -C(=O)N(Ra)-, -C(=S)N(Ra)-,-SO2N(Ra)-, -C(=O)O-, -C(=S)O-, S(=O)2O-; en donde Ra es hidrógeno, alquilo C1-6, acilo, arilo, arilo-alquilo C1-6, alcoxicarbonilo C1-6 o benciloxicarbonilo; X está ausente, o es -(CR'R'')O-, -(CR'R")S-, -(CR'R'')NRb- o alquileno C1-6, en donde R' y R'' son independientemente hidrógeno o alquilo C1-6 y Rb es hidrógeno o alquilo C1-6; R4 es arilo o heteroarilo; con la condición de que el compuesto de fórmula (1) no sea 1-(2-[4-(3,4-diclorobencil)piperazin-1-il]ciclohexil)-3-(3-metoxifenil)urea; y con la condición de que cuando el anillo A es fenilo o ciclohexilo, entonces R2 es fenilo sustituido; y prodrogas, isómeros individuales, mezclas racémicas y no racémicas de isómeros y sales farmacéuticamente aceptables de los mismos; en donde el término "fenilo opcionalmente sustituido" se refiere a un grupo fenilo que es opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en alquilo C1-6, halo-alquilo C1-6, hidroxi-alquilo C1-6, heteroalquilo, acilo, acilamino, amino, alquilamino C1-6, dialquilamino C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, -SO2NR'R'' (en donde R' y R'' son independientemente hidrógeno o alquilo C1-6), alcoxi C1-6, halo-alcoxi C1-6, alcoxicarbonilo C1-6, carbamoilo, hidroxi, halo, nitro, ciano, mercapto, metilenodioxi, y etilenodioxi; el término "acilo" se refiere a un radical -C(O)R, en donde R es hidrógeno, alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, fenilo o fenilo-alquilo C1-6; el término "acilo-alquilo C1-6" se refiere a un radical -alquileno C1-6-C(O)R en donde R es hidrógeno, alquilo C1-6, halo-alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7alquiloC1-6, fenilo opcionalmente sustituido, bencilo, hidroxi, alcoxi C1-6, amino, mono-alquilamino C1-6 o di-alquilamino C1-6; el término "arilo" se refiere a un radical hidrocarburo aromático monocíclico o bicíclico de 6 a 10 átomos del anillo que es opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en alquilo C1-6, halo-alquilo C1-6, hidroxi-alquilo C1-6, heteroalquilo, acilo, acilamino, amino, alquilamino C1-6, di-alquilamino C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, -SO2NR'R'' (en donde R' y R'' son independientemente hidrógeno o alquilo C1-6), alcoxi C1-6, halo-alcoxi C1-6, alcoxicarbonilo C1-6, carbamoilo, hidroxi, halo, nitro, ciano,mercapto, metilenodioxi, etilenodioxi; el término "acilo" se refiere a un radical -C(O)R, en donde R es hidrógeno, alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, fenilo o fenilalquilo C1-6; el término "heterociclilo" se refiere a un radical cíclico no-aromático saturado o insaturado de 3 a 8 átomos del anillo en el cual uno o dos átomos del anillo son heteroátomos seleccionados entre NRx { en donde cada Rx es independientemente hidrógeno, alquilo C1-6, acilo, alquilsulfonilo C1-6, aminosulfonilo, (alquilamino C1-6)-sulfonilo, (di-alquilamino C1-6)sulfonilo, carbamoilo,(alquilamino C1-6)carbonilo, (di-alquilamino C1-6)carbonilo, (carbamoil) alquilo C1-6, (alquilaminoC1-6)-carbonil-alquilo C1-6, o di-alquilaminocarbonilo C2-6-alquilo C1-6}, O, o S(O)n ( en donde n es un entero de 0 a 2), siendo los átomos restantes del anillo C y pudiendo el anillo heterocíclico ser opcionalmente sustituido independientemente con uno, dos o tres sustituyentes seleccionados entre alquilo C1-6, halo-alquilo C1-6, heteroalquilo, halo, nitro, ciano-alquilo C1-6, hidroxi, alcoxi C1-6, amino, mono-alquilamino C1-6, di-alquilamino C1-6, arilo-alquilo C1-6, -(X)n-C(O)R (en donde X es O ó NR', n es 0 o 1, R es hidrógeno, alquilo C1-6, halo-alquilo C1-6, hidroxi, alcoxi C1-6, amino, mono-alquilamino C1-6, di-alquilamino C1-6 o fenilo opcionalmente sustituido, y R' es hidrógeno o alquilo C1-6), -alquileno C1-6-C(O)R (en donde R es hidrógeno, alquilo C1-6, halo-alquilo C1-6, hidroxi, alcoxi C1-6, amino, mono-alquilamino C1-6, di-alquilamino C1-6 o fenilo opcionalmente sustituido) o -S(O)nRd (en donde n es un entero de 0 a 2, y Rd es hidrógeno (con la condición de que n sea 0), alquilo C1-6, halo-alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, amino, mono-alquilamino C1-6, di-alquilamino C1-6, o hidroxi-alquilo C1-6); el término "heteroarilo" se refiere a un radical monocíclico o bicíclico de 5 a 12 átomos del anillo que tiene por lo menos un anillo aromático que contiene uno, dos o tres heteroátomos del anillo seleccionados entre N, O ó S, siendo los átomos restantes del anillo C, entendiéndose que el punto de unión del radical heteroarilo estará en un anillo aromático, y el anillo heteroarilo es opcionalmente sustituido independientemente con uno o más sustituyentes, seleccionados entre alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, heteroalquilo, acilo, acilamino, amino, alquilamino C1-6, dialquilamino C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, -SO2NR'R'' (en donde R' y R'' son independientemente hidrógeno o alquilo C1-6), alcoxi C1-6, haloalcoxi C1-6, carbamoilo, hidroxi, halo, nitro, ciano, mercapto, metilenodioxi, etilenodioxi y fenilo opcionalmente sustituido; y el termino "heteroalquilo" se refiere a un radical alquilo C1-6 en donde uno, dos o tres átomos de hidrógeno han sido reemplazados con un sustituyente seleccionado independientemente entre el grupo que consiste en -ORa, -NRbRc, y -S(O)nRd (en donde n es un entero de 0 a 2), entendiéndose que el punto de unión del radical heteroalquilo es a través de un átomo de carbono, en donde Ra es hidrógeno, acilo, alquilo C1-6, cicloalquilo C3-7 o cicloalquilo C3-7-alquilo C1-6; Rb y Rc son independientemente uno de otro hidrógeno, acilo, alquilo C1-6, cicloalquilo C3-7 o cicloalquilo C3-7-alquilo C1-6; cuando n es 0, Rd es hidrógeno, alquilo C1-6, cicloalquilo C3-7, o cicloalquilo C3-7-alquilo C1-6 y cuando n es 1 o 2, Rd es alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, amino, acilamino, mono-alquilamino C1-6 y di-alquilamino C1-6.
ARP020104582A 2001-11-30 2002-11-28 Antagonistas vi del receptor ccr-3 AR037459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33465501P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
AR037459A1 true AR037459A1 (es) 2004-11-10

Family

ID=23308174

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104582A AR037459A1 (es) 2001-11-30 2002-11-28 Antagonistas vi del receptor ccr-3

Country Status (16)

Country Link
US (1) US6906073B2 (es)
EP (1) EP1453514B1 (es)
JP (1) JP2005516903A (es)
KR (1) KR100586131B1 (es)
CN (1) CN1321115C (es)
AR (1) AR037459A1 (es)
AT (1) ATE367160T1 (es)
AU (1) AU2002352122A1 (es)
BR (1) BR0214582A (es)
CA (1) CA2467966A1 (es)
DE (1) DE60221275T2 (es)
ES (1) ES2290346T3 (es)
MX (1) MXPA04004981A (es)
PL (1) PL370746A1 (es)
RU (1) RU2004120063A (es)
WO (1) WO2003045393A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087654A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
US20040235855A1 (en) * 2003-03-31 2004-11-25 Bharat Lagu Phospholipase C inhibitors for use in treating inflammatory disorders
IN2006CH00378A (en) 2003-06-30 2007-05-11 Sumitomo Chemical Co Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
AU2005245401A1 (en) * 2004-05-12 2005-12-01 Chemocentryx Aryl sulfonamides
WO2007005214A1 (en) * 2005-06-29 2007-01-11 Janssen Pharmaceutica, N.V. Substituted {4(4-phenyl-piperazin-1yl)-cyclohexyl}-urea compounds
WO2007053436A1 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
WO2009006185A1 (en) * 2007-07-03 2009-01-08 Janssen Pharmaceutica, N.V. Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
US8420640B2 (en) * 2008-08-29 2013-04-16 Treventis Corporation Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine
PE20120810A1 (es) * 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc Compuestos derivados de 5-ciano-2-(feniltio)bencensulfonamida como antagonistas de ccr3
RU2539591C2 (ru) * 2009-04-22 2015-01-20 Аксикин Фармасьютикалз, Инк. Антагонисты арилсульфонамида ccr3
DK3600312T3 (da) * 2017-03-26 2023-07-31 Takeda Pharmaceuticals Co Piperidinyl- og piperazinylsubstituerede heteroaromatiske carboxamider som modulatorer af gpr6
EP3821947A1 (en) * 2019-11-13 2021-05-19 Libra Therapeutics, Inc. Heterocyclic trpml1 agonists
CN115087440A (zh) * 2019-12-19 2022-09-20 卡斯玛治疗公司 Trpml调节剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0592921A (ja) 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
EP1029851B1 (en) * 1997-10-14 2005-04-20 Mitsubishi Pharma Corporation Piperazine compounds and medicinal use thereof
JP2002179651A (ja) * 1998-06-19 2002-06-26 Wakamoto Pharmaceut Co Ltd ベンズアニリド誘導体及び医薬組成物
EP1158980B1 (en) 1998-12-18 2005-08-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6444686B1 (en) 1998-12-18 2002-09-03 Brsitol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2350730A1 (en) 1998-12-18 2000-06-22 George V. Delucca N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035449A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
RU2004120063A (ru) 2005-06-10
KR100586131B1 (ko) 2006-06-07
EP1453514A1 (en) 2004-09-08
KR20040065570A (ko) 2004-07-22
CA2467966A1 (en) 2003-06-05
CN1321115C (zh) 2007-06-13
WO2003045393A1 (en) 2003-06-05
US20030176441A1 (en) 2003-09-18
PL370746A1 (en) 2005-05-30
BR0214582A (pt) 2004-11-03
ATE367160T1 (de) 2007-08-15
US6906073B2 (en) 2005-06-14
ES2290346T3 (es) 2008-02-16
EP1453514B1 (en) 2007-07-18
DE60221275T2 (de) 2008-05-08
MXPA04004981A (es) 2004-08-11
AU2002352122A1 (en) 2003-06-10
JP2005516903A (ja) 2005-06-09
CN1599611A (zh) 2005-03-23
DE60221275D1 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
AR037459A1 (es) Antagonistas vi del receptor ccr-3
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
NO980919D0 (no) 8-azabicyklo(3.2.1)okt-2-ene derivater, deres fremstilling og anvendelse
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
BRPI0413283B8 (pt) Composto derivado de (tio)carbamoil-ciclohexano, seu processo de preparação, amina, composição farmacêutica e uso do composto
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
DK1261602T3 (da) Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
UY26872A1 (es) Derivados de la 4- fenil piridina
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
CO5200848A1 (es) Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales
UY27322A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister

Legal Events

Date Code Title Description
FA Abandonment or withdrawal